Clinical and resource-use outcomes of risperidone long-acting injection
in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry
Current Medical Research and Opinion, 07/16/09
- Olivares JM et al. - Treatment with RLAI is associated with improved outcomes in recently diagnosed and chronic patients. However, the magnitude of improvement was higher in recently diagnosed patients.
Methods
- The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is an observational study of patients with schizophrenia who start treatment with RLAI.
- Data were recorded at baseline, retrospectively for the 12 months prior to baseline, and prospectively every 3 months for 24 months.
- Data on patients with a defined length of diagnosis were pooled from eight countries.
- Clinical Global Impression of Illness Severity (CGI-S), Global Assessment of Functioning (GAF) scores, and hospitalization data were key outcomes.
Results
- The magnitude of improvement in CGI-S scores was greater in the recent versus long-term diagnosis group.
- There were parallel improvements in GAF scores.
- The decline in the proportion of patients hospitalized from the retrospective to the prospective period was greater in the recent versus long-term diagnosis group .
- This was also true for the number of hospital and length of stay at 12 months.
- Common adverse events in both groups included psychiatric, gastrointestinal, musculoskeletal and reproductive system and breast disorders.
No comments:
Post a Comment